V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260009437 | 260006100 | 1.68 | 80 | Disease modification (D) | 2016-07-09 | 2016-07-13 | Carboplatin + Etoposide IV 3 day | N | N | 260029861 | TIP |
| 260009438 | 260006101 | 1.77 | null | Curative (C) | 2016-05-18 | 2016-05-18 | Carboplatin + Paclitaxel (weekly) | N | null | 260029862 | CARBOPLATIN + ETOPOSIDE |
| 260009439 | 260012257 | 1.75 | 165 | Palliative (P) | 2016-07-21 | 2016-07-21 | Cisplatin + Etoposide (5 day) | N | N | 260029863 | CISPLATIN + ETOPOSIDE |
| 260009440 | 260012257 | 1.73 | 0 | Curative (C) | null | 2016-03-29 | EP 1 2 or 3 day | N | N | 260029863 | TRIAL |
| 260009441 | 260012257 | 1.8 | null | Palliative (P) | 2015-05-16 | 2015-05-18 | Trial Unspecified | Y | N | 260029863 | CISPLATIN + ETOPOSIDE |
| 260009442 | 260006102 | 1.55 | 87.8 | Adjuvant (A) | 2017-05-05 | 2017-05-31 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | N | 260029872 | ETOPOSIDE + RITUXIMAB |
| 260009443 | 260006102 | null | 59.4 | Palliative (P) | 2013-10-22 | 2013-10-22 | Cisplatin + Etoposide (3 day) | 2 | N | 260029872 | CHLORAMBUCIL + RITUXIMAB |
| 260009444 | 260006103 | 1.54 | 46.6 | Adjuvant (A) | 2017-12-18 | 2018-01-23 | ETOPOSIDE + RITUXIMAB | N | N | 260029877 | BLEOMYCIN + VINCRISTINE |
| 260009445 | 260012259 | null | null | Disease modification (D) | 2015-07-25 | 2015-08-18 | GEMCARBO | N | N | 260029878 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 260009446 | 260012259 | 1.75 | 80.2 | Not known (9) | 2017-07-24 | 2017-07-28 | CISPLATIN + ETOPOSIDE | 02 | N | 260029878 | BRENTUXIMAB |
| 260009447 | 260012259 | 1.98 | 107 | Curative (C) | 2017-02-28 | 2017-03-20 | Carboplatin + Etoposide IV 3 day | Y | N | 260029878 | CISPLATIN + ETOPOSIDE |
| 260009448 | 260006104 | null | null | Disease modification (D) | 2013-04-09 | 2013-05-03 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | N | N | 260029888 | CISPLATIN + ETOPOSIDE |
| 260009449 | 260012260 | 1.78 | 67.5 | Palliative (P) | 2016-08-19 | 2016-08-24 | CISPLATIN + ETOPOSIDE | N | N | 260029894 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260009450 | 260006105 | 1.69 | null | null | 2018-07-14 | 2018-07-15 | Cisplatin + Etoposide (5 day) | 02 | N | 260029897 | CISPLATIN + ETOPOSIDE |
| 260009451 | 260006106 | 1.57 | 49.9 | Disease modification (D) | null | 2017-05-28 | CETUXIMAB | N | N | 260029902 | RITUXIMAB |
| 260009452 | 260006106 | 1.73 | null | null | null | 2013-03-08 | BLEOMYCIN + CISPLATIN + VINCRISTINE | null | null | 260029902 | ETOPOSIDE |
| 260009453 | 260012262 | null | 78.5 | Adjuvant (A) | 2015-09-24 | 2015-10-03 | FCR Oral - Cycle 1 | N | N | 260029906 | RITUXIMAB |
| 260009454 | 260006107 | null | 51.8 | Curative (C) | 2019-04-07 | 2019-04-16 | EP | N | N | 260029907 | TIP |
| 260009455 | 260015653 | 0 | 82.8 | d | 2016-07-08 | 2017-08-04 | Carboplatin + Etoposide IV 3 day | 02 | N | 260029908 | CISPLATIN + ETOPOSIDE |
| 260009456 | 260006108 | 2.05 | 94 | Not known (9) | 2016-12-22 | 2017-02-22 | BOP | Y | N | 260029909 | CARBOPLATIN + PEMETREXED |
| 260009457 | 260006108 | 1.78 | 85 | null | 2015-01-18 | 2015-01-25 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | N | 260029909 | CARBOPLATIN + ETOPOSIDE |
| 260009458 | 260006109 | 1.75 | null | null | 2015-11-25 | 2015-11-28 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 1 | N | 260029911 | CISPLATIN + ETOPOSIDE |
| 260009459 | 260012264 | 1.82 | null | Curative (C) | 2017-10-20 | 2017-11-03 | VIP | N | N | 260029914 | ETOPOSIDE |
| 260009460 | 260006110 | 1.72 | 52.9 | Curative (C) | 2013-10-11 | 2013-11-01 | Rituximab | N | N | 260029915 | TIP |
| 260009461 | 260012265 | 1.71 | 88.8 | Neo-adjuvant (N) | 2016-03-19 | 2016-03-19 | Cisplatin + Etoposide (3 day) | 2 | Y | 260029917 | CISPLATIN + ETOPOSIDE |
| 260009462 | 260012265 | null | null | Curative (C) | 2017-11-22 | 2017-11-25 | null | N | N | 260029917 | CARBOPLATIN + ETOPOSIDE |
| 260009463 | 260017453 | 1.73 | null | Disease modification (D) | 2016-03-23 | 2016-03-23 | Rituximab (SUBCUTANEOUS Maintenance) | N | N | 260029920 | CARBOPLATIN + PACLITAXEL |
| 260009464 | 260006111 | 1.81 | 60.4 | Disease modification (D) | 2016-04-21 | 2016-04-21 | Carboplatin + Etoposide IV 3 day | N | N | 260029922 | GEMCARBO |
| 260009465 | 260006111 | 1.61 | 123 | Adjuvant (A) | 2017-04-21 | 2017-08-06 | Cisplatin + Etoposide (5 day) | N | N | 260029922 | RITUXIMAB |
| 260009466 | 260006112 | 1.81 | 76.4 | Palliative (P) | 2014-05-25 | 2014-05-25 | Cisplatin + Etoposide (5 day) | 99 | N | 260029924 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260009467 | 260006112 | 1.88 | 110 | Adjuvant (A) | 2017-10-25 | 2017-11-01 | EP | N | N | 260029924 | IVA |
| 260009468 | 260006112 | 1.75 | 82 | Disease modification (D) | 2013-08-30 | 2013-08-30 | Rituximab (SUBCUTANEOUS Maintenance) | N | N | 260029924 | CISPLATIN + ETOPOSIDE |
| 260009469 | 260006112 | null | null | null | 2017-12-07 | 2017-12-19 | FEC 100 | N | N | 260029924 | CISPLATIN + RT |
| 260009470 | 260006112 | null | 64.3 | Curative (C) | 2017-09-29 | 2017-10-19 | CARBOPLATIN + GEMCITABINE | N | N | 260029924 | RITUXIMAB |
| 260009471 | 260006113 | 1.72 | 72.9 | Curative (C) | 2016-11-30 | 2016-12-03 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 02 | Y | 260029934 | CISPLATIN + ETOPOSIDE |
| 260009472 | 260012268 | 1.81 | 93 | Curative (C) | 2014-06-04 | 2014-06-10 | Rituximab | N | N | 260029936 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 260009473 | 260012268 | 1.85 | 86 | Curative (C) | 2014-11-11 | 2014-11-17 | Hydroxycarbamide | 02 | N | 260029936 | ETOPOSIDE |
| 260009474 | 260017455 | 1.52 | null | Curative (C) | 2015-08-15 | 2015-08-26 | Rituximab | 2 | N | 260029942 | CARBOPLATIN + PACLITAXEL |
| 260009475 | 260006114 | 1.73 | null | Palliative (P) | 2015-11-16 | 2015-11-18 | POMB | 2 | N | 260029943 | CISPLATIN + ETOPOSIDE |
| 260009476 | 260006114 | 1.76 | 72 | Curative (C) | 2013-08-16 | 2013-08-17 | Carboplatin + Etoposide IV 3 day | 02 | N | 260029943 | CISPLATIN + ETOPOSIDE |
| 260009477 | 260006115 | 1.43 | 59.6 | Palliative (P) | 2014-02-11 | 2014-02-18 | Rituximab | 02 | N | 260029946 | RITUXIMAB |
| 260009478 | 260006115 | 1.72 | 70.6 | Palliative (P) | 2017-04-16 | 2017-04-27 | 111 Trial (formerly BEP 111) | 02 | N | 260029946 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260009479 | 260006116 | 1.69 | null | Disease modification (D) | 2016-05-08 | 2016-05-12 | Cisplatin + Etoposide (3 day) | N | N | 260029955 | TRIAL |
| 260009480 | 260006116 | 1.63 | 79.4 | Disease modification (D) | null | 2015-08-21 | EP | N | N | 260029955 | CISPLATIN + ETOPOSIDE |
| 260009481 | 260006117 | 1.8 | 95.6 | Adjuvant (A) | 2016-02-02 | 2016-02-08 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 260029958 | CARBOPLATIN + ETOPOSIDE |
| 260009482 | 260006117 | 1.88 | 70 | Curative (C) | 2013-09-08 | 2013-10-05 | Cisplatin + Etoposide (5 day) | 2 | N | 260029958 | TIP |
| 260009483 | 260006118 | null | 101 | Adjuvant (A) | 2017-05-26 | 2017-05-27 | Cisplatin + Etoposide (5 day) | 02 | null | 260029960 | CISPLATIN + ETOPOSIDE |
| 260009484 | 260006118 | 1.6 | 77.7 | Palliative (P) | 2014-08-10 | 2014-08-12 | Rituximab | N | N | 260029960 | CISPLATIN + ETOPOSIDE |
| 260009485 | 260006119 | null | 85.5 | Adjuvant (A) | 2016-09-11 | 2016-09-13 | Doxorubicin + Olaratumab | N | N | 260029964 | RITUXIMAB |
| 260009486 | 260012274 | 1.76 | null | Palliative (P) | 2017-08-27 | 2017-08-27 | Carboplatin + Etoposide IV 3 day | 2 | N | 260029967 | CARBOPLATIN + ETOPOSIDE |